Nektar Therapeutics Unveils Promising Rezpegaldesleukin Data for Atopic Dermatitis Nektar Therapeutics shares exciting findings from the REZOLVE-AD Phase 2b study on Rezpegaldesleukin, showing significant improvements in atopic dermatitis treatment at EADV 2025.

Nektar Therapeutics Unveils Promising Rezpegaldesleukin Data for Atopic Dermatitis #United_States #San_Francisco #Nektar_Therapeutics #Rezpegaldesleukin #EADV_2025

EADV 2025 Congress Reveals Alarming Connection Between Atopic Eczema and Suicidal Thoughts New research presented at EADV 2025 highlights a troubling link between atopic eczema and significantly higher suicidal thoughts in adults.

EADV 2025 Congress Reveals Alarming Connection Between Atopic Eczema and Suicidal Thoughts #Paris #France #EADV_2025 #Atopic_Eczema #Suicidal_Thoughts

EADV Congress 2025 Uncovers Alarming Suicide Risks Linked to Atopic Eczema A recent study highlights a significant link between atopic eczema and suicidal thoughts, revealing crucial mental health implications for affected individuals.

EADV Congress 2025 Uncovers Alarming Suicide Risks Linked to Atopic Eczema #Paris #France #EADV_2025 #Atopic_Eczema #Suicidal_Ideation

New EADV 2025 Study Reveals Alarming Link Between Atopic Eczema and Suicidal Thoughts A recent study presented at EADV 2025 highlights a troubling link between atopic eczema and an increased risk of suicidal thoughts among affected adults.

New EADV 2025 Study Reveals Alarming Link Between Atopic Eczema and Suicidal Thoughts #Paris #France #mental_health #EADV_2025 #Atopic_Eczema

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 Kyowa Kirin Co., Ltd. is set to unveil results from the Phase 3 ROCKET IGNITE trial of rocatinlimab targeting atopic dermatitis at EADV 2025 in Paris.

Kyowa Kirin to Present Groundbreaking Findings on Rocatinlimab at EADV 2025 #Japan #Tokyo #Kyowa_Kirin #Rocatinlimab #EADV_2025